Astromech Raises $20M to Predict Biological Systems

The big picture: Astromech, an AI company that originated from Ben Lamm’s Colossal Biosciences, has raised $20 million at a $3.8 billion valuation. The company uses AI to study animals with extreme traits, such as cancer-resistant elephants and long-lived whales, to predict how biological systems might deteriorate.

Why it matters:

• Predictive Biology: Astromech’s AI analyzes genomic data to forecast changes and weaknesses in living systems, moving beyond reactive biological study to proactive prediction.
• Broad Applications: Its technology has implications for conservation, disease, drug resistance, and food supply, addressing critical global challenges by identifying potential biological failures.
• High Valuation: The significant $3.8 billion valuation, nearly doubling since March 2026, signals strong investor confidence in its novel approach to understanding and predicting biological system behavior.

How it works:

• Genomic AI: Astromech’s AI is trained on genomic data provided by Colossal, focusing on regulatory gene sequences to explain complex traits like longevity and disease resistance.
• Extreme Trait Analysis: The company studies animals with exceptional characteristics, such as cancer-resistant Asian elephants and 200-year-old bowhead whales, as natural experiments.
• Disease Prediction: By comparing these long-lived or disease-resistant species with their shorter-lived relatives, Astromech aims to identify and map protective factors and regulatory genes associated with cellular maintenance and longevity.

The catch: Astromech operates in a competitive landscape alongside well-funded players like Insitro and Isomorphic Labs, which focus on machine learning-based drug discovery. While Astromech aims to precede drug target identification by predicting biological failures, its current achievements are primarily research-based, with 46 genes mapped. Its high valuation, similar to its parent Colossal, comes before commercial product launches, posing a risk if predictive forecasts do not translate into tangible, monetizable outcomes quickly.